Scholarlink

Background <p>Ovarian cancer brain metastases (OCBM) are rare and have poor prognosis, with limited clinical management guidelines. This study aimed to identify prognostic factors and optimal treatment approaches for patients with OCBM.</p> Methods <p>We conducted a retrospective multicenter analysis of patients with OCBM from 12 hospitals in China from May 2010 to May 2022. The primary outcomes were overall survival (OS) and brain metastasis–specific survival (BMSS). Kaplan–Meier and Cox regression analyses were used to assess treatment outcomes and identify prognostic risk factors.</p> Results <p>In total, 129 patients with OCBM were included. The median interval from ovarian cancer diagnosis to brain metastasis (BM) was 25.74 (range: 0–103.1) months. Headache attributed to BM was the most common presenting symptom, reported in 64 (49.6%) patients, followed by paralysis in 23 (17.8%) patients. The cerebellum and brainstem were the most frequent metastatic sites (36 patients, 27.9%), followed by the frontal lobe (27 patients, 20.9%). In BMSS analysis, multiple BM lesions (hazard ratio [HR]: 2.060; 95% confidence interval [CI]: 1.308–3.244; <i>P</i> = 0.002), headache attributed to BM (HR: 1.765; 95% CI: 1.049–2.968; <i>P</i> = 0.032), and relapse lines before BM diagnosis (HR: 2.060; 95% CI: 1.308–3.244; <i>P</i> = 0.002) were independent predictors of worse BMSS. Subgroup Kaplan–Meier analysis showed that patients with a single BM lesion achieved significantly better outcomes with stereotactic radiosurgery (SRS) compared with those having multiple lesions.</p> Conclusion <p>This study demonstrates that patients with a single BM lesion may benefit from SRS, whereas those with multiple lesions require more individualized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月7日

查看全文
  • Yingying Wang,
  • Qiyue Chao,
  • Xiaoyan Lu,
  • Yichi Zhou,
  • Zhiwen Xie,
  • Shiyun Zhang,
  • Fei Xu,
  • Sikao Wu,
  • Lvzhong Hu,
  • Bo Ding,
  • Xinyi Zhang,
  • Tianmin Xu,
  • Guantai Ni,
  • Jing Liang,
  • Jinhua Zhou,
  • Yang Shen,
  • Bo Yang,
  • Shengtao Zhou,
  • Xiaojun Chen,
  • Tingyan Shi,
  • Chunyan Lan,
  • Tao Zhu,
  • Ying Zhou

摘要

Background

Ovarian cancer brain metastases (OCBM) are rare and have poor prognosis, with limited clinical management guidelines. This study aimed to identify prognostic factors and optimal treatment approaches for patients with OCBM.

Methods

We conducted a retrospective multicenter analysis of patients with OCBM from 12 hospitals in China from May 2010 to May 2022. The primary outcomes were overall survival (OS) and brain metastasis–specific survival (BMSS). Kaplan–Meier and Cox regression analyses were used to assess treatment outcomes and identify prognostic risk factors.

Results

In total, 129 patients with OCBM were included. The median interval from ovarian cancer diagnosis to brain metastasis (BM) was 25.74 (range: 0–103.1) months. Headache attributed to BM was the most common presenting symptom, reported in 64 (49.6%) patients, followed by paralysis in 23 (17.8%) patients. The cerebellum and brainstem were the most frequent metastatic sites (36 patients, 27.9%), followed by the frontal lobe (27 patients, 20.9%). In BMSS analysis, multiple BM lesions (hazard ratio [HR]: 2.060; 95% confidence interval [CI]: 1.308–3.244; P = 0.002), headache attributed to BM (HR: 1.765; 95% CI: 1.049–2.968; P = 0.032), and relapse lines before BM diagnosis (HR: 2.060; 95% CI: 1.308–3.244; P = 0.002) were independent predictors of worse BMSS. Subgroup Kaplan–Meier analysis showed that patients with a single BM lesion achieved significantly better outcomes with stereotactic radiosurgery (SRS) compared with those having multiple lesions.

Conclusion

This study demonstrates that patients with a single BM lesion may benefit from SRS, whereas those with multiple lesions require more individualized treatment strategies.